一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Immunophenotyping TCF1-expressing TILs: spatial profiling and prognostic value in operable non-small cell lung cancer.
Immunophenotyping TCF1-expressing TILs: spatial profiling and prognostic value in operable non-small cell lung cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们的研究结果支持一个更精细的框架,用于评估 TCF1+ TIL 以及肿瘤微环境中各细胞群体的 TCF1 表达,这对可手术 NSCLC 的预后判断具有重要意义。
TIL(肿瘤浸润淋巴细胞)(TILs)的空间分布和功能异质性显著影响非小细胞肺癌(NSCLC)患者的预后。尽管表达T细胞因子1(TCF1)的TILs已被认为是维持抗肿瘤免疫的关键因素,但其在肿瘤微环境中的亚群特征、定位及临床意义仍不明确。
我们对102例NSCLC肿瘤进行了多重免疫组化和免疫荧光检测,以表征TCF1 + 免疫细胞亚群,并分别分析肿瘤中心(TC)和浸润前沿(IF)。我们将这些数据与公开可用的单细胞RNA测序数据集及临床结局分析进行了整合。
CD4 + T细胞和CD79 + B细胞在TCF1 + 细胞群中占主导地位,而CD8 + T细胞仅占TCF1 + 免疫细胞的一小部分,尤其是在TC中。我们证实了肿瘤浸润性IgG + /IgA + 浆细胞共表达TCF1。PD1 + TCF1 - 细胞在TC和IF中均比PD1 + TCF1 + 细胞更常见,反映出终末分化耗竭型TILs在肿瘤微环境中占优势。生存分析显示,包括表达TCF1的细胞在内的TILs,其预后影响因组织定位不同而存在显著差异。多因素分析显示,TC中CD8 + TCF1 + 细胞增多(HR:2.5;p=0.039)和癌细胞TCF1表达增高(HR:2,7;p=0.041)以及IF中CD4 + TCF1 + 细胞(HR:0.4;p=0.043)分别成为无病生存期(DFS)的阴性和阳性独立预后标志物。将PD-L1表达与TILs整合分析,PD-L1免疫阳性与CD8 + 和PD1 + TCF1 - 细胞浸润增加相关,并与良好的DFS相关,尤其是在TC中。
The spatial distribution and functional heterogeneity of tumor-infiltrating lymphocytes (TILs) significantly impact patient outcomes in non-small cell lung cancer (NSCLC). While T cell factor 1 (TCF1) expressing TILs have emerged as key players in sustaining anti-tumor immunity, their subset characterization, localization, and clinical significance within the tumor microenvironment remain poorly defined. METHOD: We performed multiplex immunohistochemistry and immunofluorescence to characterize TCF1 + immune cell subsets, in 102 NSCLC tumors, separately analyzing the tumor center (TC) and invasive front (IF). We integrated this data with publicly available single-cell RNA-sequencing datasets and clinical outcome analyses.
CD4 + T cells and CD79 + B cells, dominate the TCF1 + landscape, while CD8 + T cells constitute a minority of TCF1 + immune cells, particularly in the TC. We demonstrated the presence of tumor-infiltrating IgG + /IgA + plasma cells co-expressing TCF1. PD1 + TCF1 - cells were more frequent than PD1 + TCF1 + cells both in the TC and IF, reflecting that terminally differentiated exhausted TILs predominate within the tumor microenvironment. Survival analyses revealed significantly different prognostic impact of TILs including TCF1-expressing cells based on topography. Multivariate analysis showed that increased CD8 + TCF1 + cells (HR: 2.5; p=0.039) and increased TCF1 expression by cancer cells (HR: 2,7; p=0.041) in the TC and CD4 + TCF1 + cells (HR: 0.4; p=0.043) in the IF emerged as negative and positive independent prognostic markers for Disease-free survival (DFS), respectively. Integrating PD-L1 expression with TILs, PD-L1 immunopositivity was correlated with increased CD8 + and PD1 + TCF1 - cell infiltration and was associated with favorable DFS especially in the TC.
Our findings support a more refined framework for TCF1 + TIL assessment and TCF1 expression across cellular populations in the tumor microenvironment, with implications for prognostication in operable NSCLC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。